Mifepristone 1200 mg daily + Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Treatment-resistant PTSD
Conditions
Treatment-resistant PTSD
Trial Timeline
Nov 15, 2024 → Nov 15, 2026
NCT ID
NCT06689254About Mifepristone 1200 mg daily + Placebo
Mifepristone 1200 mg daily + Placebo is a phase 2 stage product being developed by Corcept Therapeutics for Treatment-resistant PTSD. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06689254. Target conditions include Treatment-resistant PTSD.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06689254 | Phase 2 | Recruiting |
Competing Products
6 competing products in Treatment-resistant PTSD
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MIJ821 Subcutaneous Injection 1 mg + MIJ821 Subcutaneous Injection 4 mg + MIJ821 Subcutaneous Injection 10 mg + Placebo Subcutaneous Injection | Novartis | Phase 2 | 52 |
| MIJ821 + Placebo + Ketamine | Novartis | Phase 2 | 52 |
| Lu AF35700 + Risperidone + Olanzapine | Lundbeck | Phase 3 | 74 |
| GH001 + Placebo | GH Research | Phase 2 | 47 |
| VLY-686 + Placebo | Vanda Pharmaceuticals | Phase 2 | 44 |
| Evenamide 15 mg bid + Placebo | Newron Pharmaceuticals | Phase 3 | 69 |